Pioneers in Neuroscience

U.S. FDA approves ADUHELM™ (aducanumab-avwa) for Alzheimer’s disease

Biogen and Eisai receive FDA accelerated approval for a new therapy targeting amyloid beta plaque.

Update on Tofersen Access Program Part 1
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
How one woman found hope in the challenges of Multiple Sclerosis

When Mayu's doctor diagnosed her with MS, she faced the challenges of being a new mother and the fear of losing her ability to play the piano. She found support in her family and discovered that, even with physical struggles, she could still practice her music.

Junghae Suh | Where curiosity meets purpose

For Junghae Suh, head of Biogen’s Gene Therapy Accelerator Unit, it’s about working to deliver potentially life-transforming gene therapy medicines to patients.

Biogen updates delivered to your inbox
7/22/21 7:05 AM EDT
An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
View all news
Diversity, Equity and Inclusion

Biogen is committed to the power of diversity – in our organization and among our patients and customers. Diversity is an essential asset of complementary strengths and perspectives from which all benefit, and which must unite us, not divide us.

Where Science Meets Humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Follow us on social media